Skip to main content
SpringerLink
Log in

Apixaban a cost-efficient alternative to other NOACs

  • Clinical study
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Athanasakis K, et al. Cost-Effectiveness of Apixaban vs. Other New Oral Anticoagulants for the Prevention of Stroke: An Analysis on Patients with Non-Valvular Atrial Fibrillation in the Greek Healthcare Setting. Clinical Drug Investigation : 18 Sep 2015. Available from: URL: http://doi.org/10.1007/s40261-015-0321-7

    PubMed  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Apixaban a cost-efficient alternative to other NOACs. PharmacoEcon Outcomes News 738, 8 (2015). https://doi.org/10.1007/s40274-015-2490-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-015-2490-2

Search

Navigation